LiDCO Group Plc Master distribution agreement for Latin America (5147S)
12 March 2019 - 6:00PM
UK Regulatory
TIDMLID
RNS Number : 5147S
LiDCO Group Plc
12 March 2019
LiDCO Group Plc
("LiDCO" or the "Company")
Master distribution agreement for Latin America
LiDCO (AIM: LID), the hemodynamic monitoring company, announces
that it has signed a master distribution agreement for LiDCO
products with Brazil based Elysian Fields Medical ('Elysian
Fields') covering a number of territories across Latin America.
This agreement, which initially runs for two years, covers all
the major countries in Latin America including Brazil, Mexico,
Argentina, Chile, Uruguay, Peru, Columbia and Paraguay. Elysian
Fields will actively promote the LiDCO product range and take
responsibility for distributor management in those countries, as
well as undertake the co-ordination of regulatory and registration
requirements needed in each territory.
Elysian Fields' management team has extensive experience with
hemodynamic monitoring in the region, having previously worked for
Edwards Lifesciences, the global market leader.
Hemodynamic monitoring is an established concept in the larger
South American countries, with LiDCO management estimating that the
entire region represents up to 10% of current global demand. LiDCO
expects to register its latest monitor in Brazil and Columbia
during 2019 and the Company will work with Elysian Fields to
prioritise other market registrations. LiDCO will look to launch
its differentiated High Usage Programme in selected markets where
appropriate.
Commenting Matt Sassone, Chief Executive Officer, said: "Driving
geographical expansion from our core UK home market is a key driver
of future growth for LiDCO and accordingly we continue to expand
our distribution network globally. To date LiDCO hasn't
historically focused on Latin America, hence we are delighted to be
partnering with Elysian Fields, given their expert knowledge of the
hemodynamic monitoring market in this region."
For further information, please contact:
LiDCO Group Plc www.lidco.com
Matt Sassone (CEO) Tel: +44 (0)20 7749 1500
finnCap Tel: +44 (0)20 7600 1658
Geoff Nash / Emily Watts / Hannah Boros
(Corporate Finance)
Andrew Burdis (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or lidco@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive
hemodynamic equipment to hospitals used to monitor the amount of
blood flowing around the body and ensure that vital organs are
adequately oxygenated. LiDCO's products facilitate the application
of hemodynamic optimisation protocols for high risk patients in
both critical care units and in the operating theatre.
A number of clinical studies have shown that the optimisation of
patients' hemodynamic status in high risk patients produces better
outcomes and reduced hospital stay. LiDCO's computer-based
technology, originally developed at St Thomas' Hospital in London,
has been shown to significantly reduce morbidity and complications,
length of stay and overall costs associated with major surgery.
Key Products:
LiDCOunity: a hemodynamic monitor that combines the full suite
of LiDCO technology (non-invasive, minimally invasive and
calibrated technologies) into one platform. Designed to have the
flexibility to adapt to a patient's changing acuity, the product
enables clinicians to seamlessly transition between non-invasive,
minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus: a computer-based platform monitor used in the
Intensive Care Unit for real-time continuous display of hemodynamic
parameters including cardiac output, oxygen delivery and
fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid: a cardiac output monitor designed specifically for
use in the operating theatre for fluid and drug management. The
monitor enables anaesthetists to receive accurate and immediate
feedback on the patient's fluid and hemodynamic status - a key
measure of overall well-being before, during and after surgery. The
LiDCOrapid provides:
-- early and rapid warning of hemodynamic change to aid choice
of therapeutic route: fluid or drug
-- quantification of hemodynamic response guidance on effective
delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid
monitor to co-display Medtronic's level of consciousness parameter
('BIS(TM') )* and add the convenience of CNSystem's continuous
non-invasive blood pressure monitoring ('CNAP')**. This addresses a
growing requirement for non-invasive monitoring solutions that are
more comprehensive and can effectively replace multiple single
parameter monitors.
LiDCOview: an easy-to-use graphical display of historical
LiDCOplus and LiDCOrapid hemodynamic data.
*BIS(TM) and Bispectral Index are trademarks of Medtronic
registered in the US and foreign countries.
**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or
smartcards) and are also available in many markets as a software
for service model all of which provide a recurring revenue
stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through
a network of specialty critical care and anaesthesia distributors
in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on
AIM.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRSFAFWFFUSELD
(END) Dow Jones Newswires
March 12, 2019 03:00 ET (07:00 GMT)
Lidco (LSE:LID)
Historical Stock Chart
From Apr 2024 to May 2024
Lidco (LSE:LID)
Historical Stock Chart
From May 2023 to May 2024